Benzinga | Jun 15, 2021 07:00AM EDT

BTIG Initiates Coverage On Sarepta Therapeutics with Buy Rating, Announces Price Target of $110

BTIG analyst Yun Zhong initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Buy rating and announces Price Target of $110.